OakChart

Cumberland Pharmaceuticals Inc

CPIXHealthcare·Drug Manufacturers - Specialty & Generic·USA·Micro·NASD·Nov 11 • 12:05 PM ET

6.39+1.09 (20.57%)
2026-11-11 18:06 CET
Market cap
79.41 USD m
Revenue, TTM
31.27 USD m
Net income, TTM
-10.92 USD m
Free cash flow, TTM
0.68 USD m
EPS diluted, TTM
-0.73
P/E
-
Compare

Price

CPIX against its 20, 50 and 200-day averages
2050200
4.006.008.00325K650KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CPIXclose 6.3920-day 5.9050-day 6.66200-day 4.876.3952w high

31.1% under the 52-week high of 9.28 on 26 Aug 2026. 52-week low 1.44 on 18 Nov 2025. Last 15 sessions, 114.7% high to low

Profile

CPIX
52-week range, 63% of the way up
1.439.28

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. It operates through the following geographical segments: China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The firm products include Acetadote, Caldolor, Kristalose, Vaprisol, Talicia, Vibativ, Sancuso, Omeclamox, RediTrex, and Other. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

Employees93
IPOAug 11, 2009
Beta0.28
ATR, 14d0.74
Rel volume3.59
Short float3.43%
Insider own41.60%
Inst own20.88%

Snapshot

6 groups

Valuation

Index-
Market Cap95.74M
Enterprise Value96.26M
Income-10.92M
Sales31.27M
Book/sh1.16
Cash/sh0.26
Dividend Est.-
Dividend TTM-
Dividend Ex-DateAug 03, 2026
Dividend Gr. 3/5Y- -
Payout-
Employees93
IPOAug 11, 2009

Ratios

P/E-
Forward P/E-
PEG-
P/S3.06
P/B5.49
P/C24.80
P/FCF140.80
EV/EBITDA-
EV/Sales3.08
Quick Ratio0.96
Current Ratio0.96
Debt/Eq0.27
LT Debt/Eq0.24
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.73
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y20.68% 2.82%
Sales past 3/5Y1.95% 3.52%
EPS Y/Y TTM-244.92%
Sales Y/Y TTM-25.68%
EPS Q/Q-476.57%
Sales Q/Q-98.46%
EarningsNov 10 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own41.60%
Insider Trans0.00%
Inst Own20.88%
Inst Trans-6.64%
ROA-14.91%
ROE-42.92%
ROIC-50.43%
Gross Margin86.22%
Oper. Margin-29.58%
Profit Margin-34.92%
SMA208.31%
SMA50-4.03%
SMA20031.19%
Trades-

Technical

Shs Outstand14.98M
Shs Float8.75M
Short Float3.43%
Short Ratio3.25
Short Interest0.30M
52W High9.28 -31.14%
52W Low1.43 345.43%
Volatility12.39% 14.85%
ATR (14)0.74
RSI (14)53.76
Beta0.28
Rel Volume3.59
Avg Volume92.45K
Volume142,856

Performance

Perf Week43.92%
Perf Month-10.88%
Perf Quarter-19.11%
Perf Half Y69.90%
Perf YTD107.04%
Perf Year312.02%
Perf 3Y365.56%
Perf 5Y206.33%
Perf 10Y65.47%
Recom1.00
Target Price9.75
Prev Close5.30
Price6.39
Change %20.57%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Nov 12, 2012ReiteratedUUBSNeutral$6.50 → $5-21.8%
Feb 01, 2011ReiteratedUUBSNeutral$8 → $6.50+1.7%
Dec 16, 2010DowngradeUUBSBuy → Neutral$10 → $8+25.2%
Aug 17, 2010ReiteratedUUBSBuy$11 → $10+56.5%
Aug 17, 2010ReiteratedMMorgan JosephBuy$15 → $10+56.5%
Aug 17, 2010DowngradeJJefferiesBuy → Hold$13 → $5.50-13.9%
May 14, 2010ReiteratedMMorgan JosephBuy$21 → $15+134.7%

Peers

Mkt cap
TickerCompanyMkt cap
TLPHTalphera Inc55.28M
PCRXPacira BioSciences Inc1.46B
HRTXHeron Therapeutics Inc65.64M
COLLCollegium Pharmaceutical Inc761.35M
DERMJourney Medical Corp126.30M
ETONEton Pharmaceuticals Inc1.95B
ANIPANI Pharmaceuticals Inc1.66B
AQSTAquestive Therapeutics Inc456.87M
CRMDCorMedix Inc416.22M
CAPRCapricor Therapeutics Inc576.73M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
DFMCU.S. Micro Cap Portfolio ETF Class Shares-
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
DFATU.S. Targeted Value Portfolio-ETF Class Shares-
DFACU.S. Core Equity 2 Portfolio-ETF Class Shares-
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
DFSUDimensional US Sustainability Core 1 ETF-

News

latest 14 of 206
  • Cumberland's $77.8 Million Gain Is Accounting; The Real Story Is An Ifetroban NDA That Rests On Natural-History Data (Earnings Whispers) +20.57%
  • Cumberland: Q3 Earnings Snapshot (Associated Press)
  • CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE (PR Newswire)
  • CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTS (PR Newswire)
  • CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM (PR Newswire) -48.76% +13.79%
  • Loading…
  • Cumberland Pharmaceuticals stock tumbles on trial results (Investing.com)
  • Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results (PR Newswire)
  • CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL (PR Newswire)
  • CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM (PR Newswire) -6.69% +18.81%
  • Cumberland Pharmaceuticals Inc (CPIX) (Q2 2026) Earnings Call Highlights: Strategic ... (GuruFocus.com)
  • Cumberland: Q2 Earnings Snapshot (Associated Press) +8.22%
  • CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS (PR Newswire)
  • CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12026-05-05-0.130--0.2209.13--
2025Q42026-03-03---0.09013.68--
2025Q32025-11-040.060--0.1308.29--
2025Q22025-08-050.020--0.05010.84--
2025Q12025-05-060.160-0.08011.71--
2024Q42025-03-04---0.14010.44--
2024Q32024-11-07---0.1109.09--
2024Q22024-08-060.010--0.0809.85--
2024Q12024-05-07-0.050--0.1408.50--
2023Q42024-03-05---0.4409.35--
2023Q32023-11-070.020--0.07010.09--
2023Q22023-08-080.160-0.06010.89--
2023Q12023-05-090.110-0.0109.22--
2022Q42023-03-07---0.1709.12--
2022Q32022-11-08-0.030--0.02811.41--
2022Q22022-08-10-0.090--0.09110.30--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2010FY0.1200.1140.12045.8844.51
2011FY0.2800.2760.28051.1451.10
2012FY0.3000.3360.30048.8548.99
2013FY-0.110--0.11032.03-
2017FY-0.500--0.50041.15-
2018FY-0.450-0.550-0.44640.7438.23
2019FY-0.230--0.23047.53-
2020FY-0.220-0.220-0.22037.4436.96
2021FY-0.240--0.24035.99-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.5-0.446-0.23-0.22-0.235-0.383-0.439-0.461-0.191-0.7295
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.077-0.11-0.1360.082-0.05-0.13-0.094-0.22-0.285
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual41.1540.74234.38837.44135.98542.01139.55337.86844.52131.27
Period201720182019202020212022202320242025TTM
Sales, quarterly9.8499.08610.43611.71310.8378.29213.6799.1310.166
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual15.72315.48115.26414.98814.74314.36614.12213.95314.95714.983
Period201720182019202020212022202320242025MRQ
Shares, quarterly14.08314.01113.95314.96114.9614.95714.95714.98314.983
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue31.2744.5237.8739.5542.0135.9937.4434.3940.74
Cost of Goods Sold Incl. D&A4.3110.8111.4911.0014.4513.4213.4011.8310.36
Gross Profit26.9633.7126.3828.5527.5622.5724.0422.5630.38
Selling, General and Administrative Excl. Other32.0036.3933.4835.0333.2731.3931.5832.6637.73
Research and Development5.035.574.825.836.695.685.776.877.32
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-5.04-2.69-7.10-6.48-5.70-8.83-7.54-10.09-7.35
Interest Expense0.310.500.610.670.590.100.260.250.20
Unusual Expense0.370.11-0.912.250.00-1.15-1.16-0.800.04
Net Income Before Taxes-9.59-2.81-6.47-6.28-5.58-5.56-6.57-9.29-7.02
Income Taxes0.040.04-0.020.050.070.030.06-0.080.02
Consolidated Net Income-9.77-2.86-6.44-6.33-5.65-5.60-6.63-9.21-7.04
Net Income From Continuing Operations-9.75-2.84-6.48-6.28-5.57-5.50-6.55-9.20-6.96
Net Income-10.92-2.84-6.48-6.28-5.57-3.51-3.34-3.54-6.96
EPS (Recurring)-0.71-0.19-0.51-0.33-0.38-0.29-0.27-0.27-0.44
EPS (Basic, Before Extraordinaries)-0.73-0.19-0.46-0.44-0.38-0.24-0.22-0.23-0.45
EPS (Diluted)-0.73-0.19-0.46-0.44-0.38-0.24-0.22-0.23-0.45
EBITDA-1.832.60-1.06-0.71-0.38-4.22-2.79-5.69-4.37
Non-Operating Income (Expense)0.360.480.333.120.712.210.080.240.56
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.350.320.240.290.350.540.761.080.98
Price To Sales Ratio3.101.330.880.650.781.931.192.312.31
Gross Margin86.2275.7169.6672.1865.6162.7164.2165.6174.57
Operating Margin-29.58-6.03-18.75-16.39-13.58-24.52-20.14-29.35-18.04
Net Margin-34.92-6.37-17.11-15.88-13.26-9.75-8.92-10.29-17.09
Shares Outstanding14.9814.9613.9514.1214.3714.7414.9915.2615.48
Market Capitalization79.4179.4125.8120.7125.2453.4334.3560.6472.61

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.179.1313.688.2910.8411.7110.449.09
Cost of Goods Sold Incl. D&A0.003.213.282.033.052.463.472.44
Gross Profit0.175.9210.406.277.799.266.966.65
Selling, General and Administrative Excl. Other3.108.9411.738.228.507.928.548.83
Research and Development0.771.461.551.251.471.301.291.31
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.93-3.02-1.34-1.96-0.711.34-1.57-2.19
Interest Expense0.000.090.110.110.110.160.220.14
Unusual Expense0.220.110.030.010.040.040.27-0.49
Net Income Before Taxes-3.10-3.14-1.41-1.94-0.731.25-1.96-1.53
Income Taxes0.000.000.020.010.010.01-0.060.01
Consolidated Net Income-3.10-3.29-1.43-1.95-0.741.25-1.90-1.54
Net Income From Continuing Operations-3.11-3.29-1.41-1.94-0.741.26-1.90-1.54
Net Income-4.28-3.29-1.41-1.94-0.741.26-1.90-1.54
EPS (Recurring)-0.28-0.21-0.09-0.13-0.050.08-0.12-0.13
EPS (Basic, Before Extraordinaries)-0.29-0.22-0.09-0.13-0.050.08-0.14-0.11
EPS (Diluted)-0.29-0.22-0.09-0.13-0.050.08-0.14-0.11
EBITDA-3.94-1.46-0.01-0.630.612.650.21-0.79
Non-Operating Income (Expense)0.060.080.080.130.130.130.110.31
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.060.080.140.060.060.060.060.06
Price To Sales Ratio3.101.161.341.131.191.570.870.49
Gross Margin100.0064.8476.0075.5671.9079.0266.7273.16
Operating Margin-1,762.64-33.10-9.77-23.58-6.5411.41-15.09-24.08
Net Margin-2,569.04-36.03-10.32-23.40-6.8410.73-18.24-16.99
Shares Outstanding14.9814.9814.9614.9614.9614.9613.9514.01
Market Capitalization79.4137.6946.1636.1938.8745.8225.8113.99

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments11.4417.9618.3219.7627.0424.7528.2136.2350.09
Short Term Receivables16.9411.709.7613.166.8812.387.867.848.40
Inventories6.234.004.619.868.4310.648.8712.086.74
Other Current Assets2.452.793.033.083.342.205.222.963.47
Total Current Assets37.0636.4535.7145.8745.6949.9750.1659.1268.68
Net Property, Plant & Equipment8.616.457.045.501.472.603.710.770.53
Total Investments and Advances3.990.000.000.000.000.000.000.000.00
Intangible Assets14.9418.8923.5231.5024.8429.0031.8034.4421.44
Deferred Tax Assets-----0.661.342.062.15
Other Assets12.2313.7915.5010.0512.4714.8918.8518.282.49
Total Assets76.8275.5881.7892.9384.4697.13105.86114.6795.30
Short Term Debt Incl. Current Port. of LT Debt0.475.460.350.170.971.020.920.000.00
Accounts Payable18.5713.9114.0410.829.6413.409.9911.098.98
Other Current Liabilities17.7112.2513.6017.598.6711.2513.2416.718.71
Total Current Liabilities36.7431.6227.9828.5819.2825.6724.1527.8017.69
Long Term Debt9.7115.1218.0820.7915.0916.0620.5820.009.80
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities-----0.661.311.972.07
Other Liabilities5.826.306.457.597.497.868.749.321.82
Total Liabilities52.2853.0452.5256.9541.8650.2554.7859.1031.38
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity24.8822.8529.6036.2742.8146.9951.1255.8464.12
Total Shareholders Equity24.8822.8529.6036.2742.8146.9951.1255.8464.12
Accumulated Minority Interest-0.34-0.31-0.34-0.29-0.21-0.12-0.04-0.27-0.20
Total Equity24.5422.5529.2635.9742.6046.8751.0955.5763.92
Total Liabilities & Stockholders Equity76.8275.5881.7892.9384.4697.13105.86114.6795.30
Book Value Per Share1.661.642.102.522.903.143.353.614.08
Tangible Book Value Per Share0.660.280.430.331.221.201.271.382.71
Full-Time Employees939191858390948084
Price to Book Ratio4.551.040.550.651.250.731.191.301.38
Return on Assets-3.72-8.24-7.19-6.28-6.06-6.45-8.35-6.63-8.31
Return on Equity-11.88-24.71-19.07-14.09-12.25-13.34-17.21-11.61-11.62
Return on Invested Capital-8.20-17.07-13.17-9.76-6.06-5.30-4.93-9.18-10.79
Quick Ratio0.841.031.111.261.931.531.711.693.50
Current Ratio1.011.151.281.602.371.952.082.133.88

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-10.94-2.86-6.44-6.33-5.65-3.60-3.42-3.55-7.04
Depreciation3.205.296.045.775.334.614.754.402.98
Other Funds (Non Cash)4.210.35-1.502.02-1.67-2.840.520.501.21
Funds from Operations-3.522.77-1.911.46-1.99-1.841.871.42-2.76
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital4.272.161.294.6310.448.183.531.585.87
Cash from Operating Activities0.754.93-0.616.098.456.345.413.003.11
Capital Expenditures-0.12-0.18-0.18-0.45-2.07-0.35-2.11-1.02-4.28
Net Assets From Acquisitions0.000.000.000.00-13.500.000.00-5.00-20.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-5.40-4.480.000.000.00-0.200.008.32-3.45
Purchase of Investments-5.40-4.480.000.000.00-0.200.00-11.75-20.11
Sale Or Maturity of Investments-0.000.000.000.000.000.0020.0616.66
Other Uses-0.23-0.050.000.000.00-0.03-0.100.000.00
Other Sources0.000.000.240.351.900.090.460.00-
Cash from Investing Activities-5.75-4.710.06-0.11-13.67-0.50-1.762.30-27.72
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock5.195.00-0.58-0.74-1.05-1.39-1.99-3.49-3.06
Repurchase of Common Pref Stock-0.07-0.26-0.58-0.74-1.05-1.39-1.85-3.49-2.88
Sale of Common Pref Stock5.275.270.000.000.000.00-0.140.00-0.18
Proceedsfrom Stock Options5.275.270.000.000.000.00-0.140.00-0.38
Issuance or Reduction of Debt, Net-5.24-10.042.49-3.421.200.00-3.50-1.5010.20
Change in Long Term Debt-5.24-10.042.49-3.421.200.00-3.50-1.5010.20
Issuance of Long Term Debt0.000.0038.4931.4852.9059.0059.0076.0056.00
Reduction of Long Term Debt-5.24-10.04-36.00-34.89-51.70-59.00-62.50-77.50-45.80
Net Financing Active Other Cash Flow-7.17-1.71-1.72-3.27-2.21-2.17-1.62-0.030.00
Other Financing Activities Uses-1.91-1.71-1.72-3.27-2.21-2.17-1.62-1.030.00
Cash from Financing Activities-7.22-6.750.20-7.42-2.06-3.55-7.11-5.037.14
Net Change in Cash-12.22-6.52-0.36-1.44-7.282.29-3.460.27-17.47
Free Cash Flow0.684.83-0.685.818.356.245.262.762.66
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow141.9512.23-4.413.9211.168.5028.7535.43
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.020.070.08

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments3.8611.0111.4415.2016.0915.11
Short Term Receivables13.4214.2616.9410.4310.3210.49
Inventories0.035.456.232.933.224.10
Other Current Assets16.332.072.451.381.582.18
Total Current Assets33.6432.7937.0629.9431.2131.88
Net Property, Plant & Equipment7.537.868.617.867.427.48
Total Investments and Advances0.003.843.990.000.000.00
Intangible Assets0.0413.7114.9415.9216.9017.90
Other Assets21.6612.8012.2312.1712.3812.68
Total Assets62.8871.0076.8265.9067.9169.94
Short Term Debt Incl. Current Port. of LT Debt0.500.490.470.400.390.37
Accounts Payable19.5516.5418.5713.8313.4513.93
Other Current Liabilities15.1417.4717.7110.0810.1411.22
Total Current Liabilities35.1934.4936.7424.3123.9725.52
Long Term Debt4.219.589.719.849.9510.07
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities6.375.625.825.956.306.01
Total Liabilities45.7749.6952.2840.1040.2341.60
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity17.4421.6424.8826.1227.9928.66
Total Shareholders Equity17.4421.6424.8826.1227.9928.66
Accumulated Minority Interest-0.33-0.33-0.34-0.32-0.31-0.32
Total Equity17.1121.3024.5425.8027.6828.34
Total Liabilities & Stockholders Equity62.8871.0076.8265.9067.9169.94
Book Value Per Share1.161.441.661.751.871.92
Tangible Book Value Per Share1.160.530.660.680.740.72
Full-Time Employees--93---
Price to Book Ratio4.551.511.771.291.362.00
Return on Assets-14.91-10.48-3.72-4.67-4.00-4.33
Return on Equity-42.92-29.36-11.88-13.08-10.79-11.67
Return on Invested Capital-19.75-10.54-4.08-5.40-1.953.25
Quick Ratio0.960.790.841.111.171.09
Current Ratio0.960.951.011.231.301.25

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.27-3.29-1.43-1.95-0.741.25
Depreciation-1.011.561.331.321.321.32
Other Funds (Non Cash)3.960.120.130.000.000.21
Funds from Operations-1.33-1.610.03-0.620.592.77
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.502.00-0.030.810.261.13
Cash from Operating Activities0.170.390.000.190.843.90
Capital Expenditures-0.03-0.02-0.04-0.03-0.04-0.07
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-1.750.00-3.03-0.610.33-1.16
Purchase of Investments-1.750.00-3.03-0.610.33-1.16
Sale Or Maturity of Investments0.000.00----
Other Uses-0.15-0.040.00-0.050.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-1.93-0.06-3.07-0.690.29-1.23
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.00-0.065.27-0.01-0.01-0.25
Repurchase of Common Pref Stock0.00-0.060.00-0.01-0.01-0.25
Sale of Common Pref Stock0.000.005.270.000.000.00
Proceedsfrom Stock Options0.000.005.270.000.000.00
Issuance or Reduction of Debt, Net-5.240.000.000.000.00-10.04
Change in Long Term Debt-5.240.000.000.000.00-10.04
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-5.240.000.000.000.00-10.04
Net Financing Active Other Cash Flow-0.15-0.70-5.95-0.38-0.144.76
Other Financing Activities Uses-0.15-0.70-0.68-0.38-0.14-0.51
Cash from Financing Activities-5.39-0.76-0.68-0.39-0.15-5.53
Net Change in Cash-7.14-0.44-3.75-0.890.98-2.86
Free Cash Flow0.130.390.000.160.823.85
Price to Free Cash Flow141.9535.4712.316.937.1312.06

Revenue breakdown

Product - Acetadote2024: 185.18K 2025: 508.17K
Product - Caldolor2024: 4.96M 2025: 4.66M
Product - Kristalose2024: 15.32M 2025: 10.54M
Product - Omeclamox-Pak2024: -3.08K 2025: -10.44K
Product - Other2024: 1.33M 2025: 4.13M
Product - RediTrex2024: 90.24K 2025: 11.39K
Product - Sancuso2024: 9.01M 2025: 11.91M
Product - Talicia2025: 3.31M
Product - Vaprisol2024: -174.54K 2025: -18.35K
Product - Vibativ2024: 7.16M 2025: 9.48M
United States2024: 37.87M 2025: 44.52M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.43%0.3M8.8M85.37K
2026-10-153.84%0.3M8.8M87.33K
2026-09-303.99%0.3M8.8M101.24K
2026-09-152.89%0.3M8.8M104.52K
2026-08-313.14%0.3M8.8M109.98K
2026-08-143.73%0.3M8.8M133.00K
2026-07-314.42%0.4M8.8M148.40K
2026-07-154.26%0.4M8.8M991.42K
2026-06-302.77%0.2M8.8M968.21K
2026-06-153.87%0.3M8.8M955.95K
2026-05-294.06%0.4M8.7M984.83K
2026-05-155.20%0.5M8.7M979.53K
2026-04-306.00%0.5M8.7M999.81K
2026-04-151.29%0.1M8.7M129.47K
2026-03-311.27%0.1M8.6M162.03K
2026-03-131.65%0.1M8.6M214.62K
2026-02-272.09%0.2M8.6M208.77K
2026-02-132.24%0.2M8.6M198.04K
2026-01-300.87%0.1M8.7M175.15K
2026-01-151.16%0.1M8.7M148.64K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.502.604.202.106.6746.000.000.971-0.0130.001
call5.000.152.800.835.3913140.000.780-0.1060.003
call7.500.050.150.151.2241502070.230-0.0210.003
call10.000.000.100.054.4641010.000.362-0.0890.004
call12.500.001.850.162.77750.000.000.092-0.0250.002
call15.000.000.950.003.2960.000.000.081-0.0270.001
put2.500.000.050.0510.27326.000.00-0.083-0.0870.002
put5.000.001.450.506.21530.000.00-0.220-0.1050.003
put7.500.503.200.576.45779.000.00-0.751-0.0190.003
put10.003.305.000.005.6420.000.00-0.888-0.0210.002
put12.505.807.500.007.1640.000.00-0.908-0.0240.002
put15.008.309.900.007.5470.000.00-0.919-0.0260.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-10-268-KCurrent report2026-10-26SEC
2026-10-238-KCurrent report2026-10-23SEC
2026-09-118-K/A2026-04-21SEC
2026-08-288-KCurrent report2026-08-28SEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-138-KCurrent report2026-07-13SEC
2026-07-018-KCurrent report2026-06-29SEC
2026-06-258-KCurrent report2026-06-24SEC
2026-05-26DEFM14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-15PREM14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-15SEC
2026-05-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-058-KCurrent report2026-05-05SEC
2026-04-248-KCurrent report2026-04-21SEC
2026-04-23DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-238-KCurrent report2026-04-22SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-18SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-18SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-18SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-18SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-18SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-18SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-18SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-18SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-18SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-18SEC
2026-03-184Statement of changes in beneficial ownership of securities2026-03-16SEC
2026-03-12ARSAnnual report to security holders. 2026-03-12SEC
2026-03-09DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Diversified Trust Co4.67%
Ikarian Capital, LLC3.36%
RENAISSANCE TECHNOLOGIES LLC3.19%
VANGUARD CAPITAL MANAGEMENT LLC2.53%
DIMENSIONAL FUND ADVISORS LP1.23%
BOOTHBAY FUND MANAGEMENT, LLC0.75%
GEODE CAPITAL MANAGEMENT, LLC0.73%
PERCEPTIVE ADVISORS LLC0.65%
CITADEL ADVISORS LLC0.49%
BlackRock, Inc.0.42%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.83%
VANGUARD EXTENDED MARKET INDEX FUND0.67%
Dimensional U.S. Small Cap ETF0.33%
U.S. MICRO CAP PORTFOLIO0.32%
Fidelity Extended Market Index Fund0.31%
U.S. Targeted Value Portfolio0.25%
iShares Micro-Cap ETF0.19%
Ultra-Small Company Market Fund0.17%
Nationwide Bailard Small Cap Value Fund0.16%
Fidelity Total Market Index Fund0.12%

OakChart. CPIX. Cached 15 minutes.

Some panels did not load: insider.